CCR2 receptor antagonists and uses thereof

US12209094B2 · kind B2 · utility

Assignee

• Centrexion Therapeutics Corporation · US

Inventors

• Heiner Ebel · Biberach an der Riß, DE
• Sara Frattini · Castelleone, IT
• Kai Gerlach · Biberach, DE
• Riccardo Giovannini · Verona, IT
• Christoph Hoenke · Ingelheim am Rhein, DE
• Rocco Mazzaferro · San Giuliano Milanese, IT
• Marco Santagostino · Magenta, IT
• Stefan Scheuerer · Warthausen, DE
• Christofer Tautermann · Biberach, DE
• Thomas Trieselmann · Ochsenhausen, DE

Key dates

• Filing date: Jul 31, 2023
• Grant date: Jan 28, 2025
• Expiry date: Jul 31, 2043

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D405/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.